FENNEC PHARMACEUTICALS INC. - Common stock, no par value (the "Shares") (FENC) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2017 to Q4 2025

Type / Class
Equity / Common stock, no par value (the "Shares")
Symbol
FENC on Nasdaq
Shares outstanding
34,145,841
Price per share
$7.59
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
15,538,482
Total reported value
$119,646,345
% of total 13F portfolios
0%
Share change
+1,579,597
Value change
+$11,219,093
Number of holders
95
Price from insider filings
$7.59
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of FENNEC PHARMACEUTICALS INC. - Common stock, no par value (the "Shares") (FENC) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Sonic Fund II, L.P. 8.2% $21,503,685 2,799,959 Kam Lawrence 31 Dec 2025
Rosalind Advisors, Inc. 9.8% +29% $21,095,731 +$5,145,600 2,746,840 +32% Rosalind Advisors, Inc. 31 Dec 2025
Southpoint Capital Advisors LP 8% $21,135,329 2,744,741 Southpoint Master Fund, LP 31 Dec 2025
Solas Capital Management, LLC 8.2% +17% $12,807,729 +$1,862,809 2,250,919 +17% Solas Capital Management, LLC 31 Dec 2024
DG Capital Management, LLC 4.1% $6,342,597 1,114,692 DG Capital Management, LLC 31 Dec 2024

As of 31 Dec 2025, 95 institutional investors reported holding 15,538,482 shares of FENNEC PHARMACEUTICALS INC. - Common stock, no par value (the "Shares") (FENC). This represents 46% of the company’s total 34,145,841 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of FENNEC PHARMACEUTICALS INC. - Common stock, no par value (the "Shares") (FENC) together control 43% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Southpoint Capital Advisors LP 8% 2,744,741 -33% 0.49% $21,134,506
Rosalind Advisors, Inc. 7.7% 2,613,508 +26% 7.7% $20,124,012
Solas Capital Management, LLC 7.5% 2,560,726 +17% 11% $19,717,590
AIGH Capital Management LLC 4.6% 1,581,501 +132% 3.6% $12,177,558
BlackRock, Inc. 3.6% 1,234,277 +1.9% 0% $9,503,934
VANGUARD GROUP INC 3.1% 1,067,651 +12% 0% $8,220,912
AWM Investment Company, Inc. 2.1% 711,869 0.53% $5,481,391
STATE STREET CORP 1% 352,775 +3.4% 0% $2,716,368
GEODE CAPITAL MANAGEMENT, LLC 0.87% 297,100 -1.2% 0% $2,287,669
MORGAN STANLEY 0.71% 242,476 +4.3% 0% $1,867,066
Apis Capital Advisors, LLC 0.6% 204,000 0.27% $1,570,800
CITADEL ADVISORS LLC 0.58% 199,749 +86% 0% $1,538,067
GENDELL JEFFREY L 0.41% 139,559 0% 0.02% $1,074,605
MARSHALL WACE, LLP 0.37% 127,693 0% $983,236
Lion Point Capital, LP 0.33% 112,434 -8.6% 4.5% $865,742
NORTHERN TRUST CORP 0.33% 112,092 -14% 0% $863,108
Potomac Capital Management, Inc. 0.28% 95,100 0% 0.61% $732,270
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.24% 83,005 +170% 0.01% $639,139
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.17% 57,249 0% 0% $440,817
Trexquant Investment LP 0.15% 51,380 0% $395,626
STATE OF WISCONSIN INVESTMENT BOARD 0.15% 51,000 +59% 0% $392,700
Hartford Financial Management Inc. 0.15% 50,646 0% 0.1% $389,975
Stonepine Capital Management, LLC 0.15% 50,000 0.31% $385,000
Bank of New York Mellon Corp 0.14% 49,219 -5.9% 0% $378,989
Qube Research & Technologies Ltd 0.13% 44,692 0% $344,128

Institutional Holders of FENNEC PHARMACEUTICALS INC. - Common stock, no par value (the "Shares") (FENC) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 15,538,482 $119,646,345 +$11,219,093 $7.70 95
2025 Q3 13,863,242 $129,757,954 +$2,614,052 $9.36 83
2025 Q2 13,599,927 $112,877,891 +$2,365,581 $8.30 77
2025 Q1 13,390,166 $81,552,976 -$1,522,792 $6.09 68
2024 Q4 16,048,764 $101,424,546 +$7,283,101 $6.32 64
2024 Q3 14,931,283 $74,650,166 +$2,539,947 $5.00 62
2024 Q2 14,360,522 $87,742,748 -$6,402,237 $6.11 62
2024 Q1 14,487,904 $161,105,911 -$6,099,282 $11.12 64
2023 Q4 15,010,968 $168,423,713 +$8,238,895 $11.22 55
2023 Q3 14,291,968 $107,334,991 +$1,444,870 $7.51 54
2023 Q2 14,066,767 $124,212,045 +$9,438,707 $8.83 54
2023 Q1 13,040,023 $108,481,973 +$4,197,539 $8.32 53
2022 Q4 12,451,231 $119,532,387 -$8,641,346 $9.60 42
2022 Q3 11,367,575 $92,077,143 +$913,826 $8.10 29
2022 Q2 11,273,521 $63,103,949 -$835,989 $5.63 24
2022 Q1 11,437,604 $64,049,354 +$542,291 $5.60 24
2021 Q4 11,346,536 $49,924,524 -$2,427,096 $4.40 26
2021 Q3 11,649,016 $109,719,412 -$3,040,624 $9.42 30
2021 Q2 12,077,739 $88,042,799 -$14,218,632 $7.29 36
2021 Q1 14,373,653 $89,259,363 -$593,443 $6.21 49
2020 Q4 14,462,317 $107,736,409 +$5,043,456 $7.45 48
2020 Q3 13,830,913 $83,811,378 -$1,125,208 $6.06 51
2020 Q2 13,870,610 $115,816,682 +$37,949,605 $8.35 53
2020 Q1 9,462,229 $56,207,308 +$983,452 $5.94 25
2019 Q4 9,292,337 $60,284,409 -$38,066 $6.48 26
2019 Q3 8,465,309 $40,716,816 -$1,958,704 $4.81 21
2019 Q2 8,988,085 $35,952,664 -$3,100,726 $4.00 25
2019 Q1 9,638,104 $46,743,906 -$525,691 $4.85 44
2018 Q4 9,742,725 $62,159,250 +$1,863,710 $6.38 45
2018 Q3 9,435,050 $77,373,042 -$276,921 $8.20 45
2018 Q2 9,392,799 $98,080,873 +$18,177,598 $10.44 43
2018 Q1 7,623,491 $92,186,011 +$4,858,661 $12.09 21
2017 Q4 6,949,133 $69,588,032 +$18,006,732 $10.00 16
2017 Q3 5,214,611 $57,723,043 +$57,723,043 $11.03 10